Key Highlights

  • BioAtla shares settled down 45% at $1.73.
  • Nasdaq's Listing Council upheld a delisting decision against the company.
  • BioAtla had already failed the minimum bid-price and stockholders' Equity tests.
  • The company can still trade while delisting mechanics run, but typically moves to OTC markets afterward.

BioAtla, Inc. (NASDAQ: BCAB) shares settled down 45% at $1.73 after Nasdaq's Listing Council upheld a delisting decision, the last internal appeal stop after the company had already failed the minimum bid-price and stockholders' equity tests.

What Happened

BioAtla is a clinical-stage antibody company built around conditionally active biologics, or CABs, antibodies designed to bind within the tumor microenvironment while sparing healthy tissue. The exchange decision does not erase that underlying technology platform, but it does affect liquidity, as funds that cannot hold unlisted names are typically required to sell.

Market Reaction

Shares fell sharply as the sustained delisting order removed the listing premium from the stock; failing both the bid-price and stockholders' equity tests together is generally viewed as a more serious signal than a single missed test.

Outlook

Holders are likely to focus on whether remaining cash can fund a trial long enough to matter off-exchange, and whether a reverse split combined with a Capital raise remains feasible following this decline.